Lopa Silvia, Libonati Francesca, Mareschi Katia, Talò Giuseppe, Brambilla Stefania, Raffo Vincenzo, Labanca Luciana, Zagra Luigi, Moretti Matteo, de Girolamo Laura, Colombini Alessandra
Cell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via C. Belgioioso 173, 20157 Milan, Italy.
Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via C. Belgioioso 173, 20157 Milan, Italy.
Biomedicines. 2024 Apr 9;12(4):833. doi: 10.3390/biomedicines12040833.
Macrophage-based co-cultures are used to test the immunomodulatory function of candidate cells for clinical use. This study aimed to characterize a macrophage polarization model using human platelet lysate (hPL) as a GMP-compliant alternative to Fetal Bovine Serum (FBS). Primary human monocytes were differentiated into unpolarized (M0) or polarized (M1, M2a, and M2c) macrophages in an hPL- or FBS-based medium. The protein secretion profiles and expression of phenotypic markers (CD80 for M1, CD206 for M2a, and CD163 for M2c) were analyzed. Subsequently, chondrocytes were tested in an hPL-based co-culture model to assess their immunomodulatory function in view of their possible use in patients with osteoarthritis. The results showed similar marker regulation between hPL and FBS cultures, but lower basal levels of CD206 and CD163 in hPL-cultured macrophages. Functional co-culture experiments with chondrocytes revealed increased CD206 expression both in hPL and in FBS, indicating an interaction between macrophages and chondrocytes. While markers in FBS-cultured macrophages were confirmed in hPL-cultured cells, the interpretation of marker modulation in immunomodulatory assays with hPL-based cultures should be carried out cautiously due to the observed differences in the basal marker levels for CD206 and CD163. This research underscores the utility of hPL as a GMP-compliant alternative to FBS for macrophage-based co-cultures and highlights the importance of understanding marker expressions in different culture conditions.
基于巨噬细胞的共培养用于测试候选细胞在临床应用中的免疫调节功能。本研究旨在表征一种巨噬细胞极化模型,该模型使用人血小板裂解物(hPL)作为符合药品生产质量管理规范(GMP)的胎牛血清(FBS)替代品。在基于hPL或FBS的培养基中,将原代人单核细胞分化为未极化(M0)或极化(M1、M2a和M2c)巨噬细胞。分析了蛋白质分泌谱和表型标志物(M1的CD80、M2a的CD206和M2c的CD163)的表达。随后,在基于hPL的共培养模型中对软骨细胞进行测试,以评估其在骨关节炎患者中可能的应用时的免疫调节功能。结果显示,hPL和FBS培养物之间的标志物调节相似,但hPL培养的巨噬细胞中CD206和CD163的基础水平较低。与软骨细胞的功能性共培养实验表明,hPL和FBS中CD206的表达均增加,表明巨噬细胞与软骨细胞之间存在相互作用。虽然FBS培养的巨噬细胞中的标志物在hPL培养的细胞中得到了证实,但由于观察到CD206和CD163基础标志物水平存在差异,在基于hPL培养物的免疫调节试验中对标志物调节的解释应谨慎进行。本研究强调了hPL作为基于巨噬细胞的共培养中符合GMP的FBS替代品的实用性,并突出了了解不同培养条件下标志物表达的重要性。